ondasdechoque.org
PT-BR

Plantar heel pain / plantar fasciopathy · Follow-up analysis · 2025

How did heel pain change over a year for people in a shockwave trial?

In this follow-up of 200 adults from a heel-pain trial, pain during activity fell from about 6 to about 3 out of 10 over one year. Everyone had insoles and advice; some also had shockwave, sham shockwave or exercise, and this analysis looked at all the groups together.

Improved over time
adults with heel pain
200
treatment groups, looked at together
4
months of follow-up
12

Good to know: This analysis combined all four treatment groups, so it shows how people did overall.

Røe C, Heide M, Søberg HL, et al. Journal of Foot and Ankle Research, 2025 · Read the paper ↗

The treatment

Shockwave + insoles and advice

Radial

Radial wavesSpread out from the skin; strongest near the surface
Numbing
Not mentioned
Device
Not named in the paper
Everyone also got
Advice and custom insoles

Compared with: Insoles and advice alone, or with sham shockwave or heavy, slow exercise

Settings are what each study used, not a prescription.

Who took part

200 adults aged 18 to 70 at a Norwegian specialist clinic; 76 had pain in both heels.

Side effects

This analysis did not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

200 adults aged 18–70 in a Norwegian specialist outpatient clinic; 160–182 attended each 3-, 6- and 12-month follow-up. 76 (38%) had bilateral heel pain.

Advice and customized orthosis

The secondary trajectory analysis pools participants because parent-trial outcome trajectories did not differ by arm; per-arm counts are not given in this paper.

Advice/orthosis plus radial ESWT

The secondary trajectory analysis pools participants because parent-trial outcome trajectories did not differ by arm; per-arm counts are not given in this paper.

Advice/orthosis plus sham radial ESWT

The secondary trajectory analysis pools participants because parent-trial outcome trajectories did not differ by arm; per-arm counts are not given in this paper.

Advice/orthosis plus heavy-slow exercise

The secondary trajectory analysis pools participants because parent-trial outcome trajectories did not differ by arm; per-arm counts are not given in this paper.

Pain during activity (PainA): linear time trajectory3 reported outcomes
01
Baseline through 3, 6 and 12 months

Pain during activity (PainA): linear time trajectory

Numeric Rating Scale (0–10) NRS points per model-coded time unit; time-unit coding not specified

β-1.14Uncertainty interval unavailablep <0.01

Within-cohort linear time coefficient, pooled across treatment arms; not an ESWT treatment contrast

200 participants in this estimate

Linear mixed-effects model with reported covariates

The model reports a significant average trajectory over time. The coefficient is per model-coded time unit; the paper does not define that unit in the table.

Analysis details and source

Cohort-level longitudinal association; randomized intervention arms were pooled after no between-arm trajectory differences in the primary analysis. This coefficient is not an isolated treatment effect.

02
Baseline through 3, 6 and 12 months

Pain during rest (PainR): linear time trajectory

Numeric Rating Scale (0–10) NRS points per model-coded time unit; time-unit coding not specified

β-0.6Uncertainty interval unavailablep <0.01

Within-cohort linear time coefficient, pooled across treatment arms; not an ESWT treatment contrast

200 participants in this estimate

Linear mixed-effects model with reported covariates

The model reports a significant average trajectory over time. The coefficient is per model-coded time unit; the paper does not define that unit in the table.

Analysis details and source

Cohort-level longitudinal association; randomized intervention arms were pooled after no between-arm trajectory differences in the primary analysis. This coefficient is not an isolated treatment effect.

06
Baseline to 12-month trajectory; time × pain laterality interaction

Pain-at-rest trajectory difference associated with bilateral versus unilateral pain

Numeric Rating Scale (0–10) NRS points per model time unit

β interaction0.25CI 95% 0.02 to 0.48p = 0.03

Difference in modeled time trajectory: bilateral versus unilateral pain

200 participants in this estimate

Linear mixed-effects model

-0.1Equal results 00.5

The interaction indicates a different modeled trajectory for bilateral versus unilateral pain; it is not a randomized treatment effect.

Analysis details and source

Coefficient per model-coded time unit; the time-unit coding is not specified in the table. The authors report that participants with bilateral pain improved in pain at rest and foot function up to 6 months but showed a lack of improvement from 6 to 12 months. Table 4's title calls PainR "pain during activity"; the Methods, Table 3, the Figure 3 caption and the Results text use PainR for pain at rest, as here.

Foot Function Index Revised Short Form: linear time trajectory1 reported outcome
03
Baseline through 3, 6 and 12 months

Foot Function Index Revised Short Form: linear time trajectory

FFI-RS (0–100) FFI-RS points per model-coded time unit; time-unit coding not specified

β-7.69Uncertainty interval unavailablep <0.01

Within-cohort linear time coefficient, pooled across treatment arms; not an ESWT treatment contrast

200 participants in this estimate

Linear mixed-effects model with reported covariates

The model reports a significant average trajectory over time. The coefficient is per model-coded time unit; the paper does not define that unit in the table.

Analysis details and source

Cohort-level longitudinal association; randomized intervention arms were pooled after no between-arm trajectory differences in the primary analysis. This coefficient is not an isolated treatment effect.

RAND-12 physical component score: linear time trajectory1 reported outcome
04
Baseline through 3, 6 and 12 months

RAND-12 physical component score: linear time trajectory

RAND-12 PCS (0–100) score points per model-coded time unit; time-unit coding not specified

β2.6Uncertainty interval unavailablep <0.01

Within-cohort linear time coefficient, pooled across treatment arms; not an ESWT treatment contrast

200 participants in this estimate

Linear mixed-effects model with reported covariates

The model reports a significant average trajectory over time. The coefficient is per model-coded time unit; the paper does not define that unit in the table.

Analysis details and source

Cohort-level longitudinal association; randomized intervention arms were pooled after no between-arm trajectory differences in the primary analysis. This coefficient is not an isolated treatment effect.

RAND-12 mental component score: linear time trajectory1 reported outcome
05
Baseline through 3, 6 and 12 months

RAND-12 mental component score: linear time trajectory

RAND-12 MCS (0–100) score points per model-coded time unit; time-unit coding not specified

β1.56Uncertainty interval unavailablep <0.01

Within-cohort linear time coefficient, pooled across treatment arms; not an ESWT treatment contrast

200 participants in this estimate

Linear mixed-effects model with reported covariates

The model reports a significant average trajectory over time. The coefficient is per model-coded time unit; the paper does not define that unit in the table.

Analysis details and source

Cohort-level longitudinal association; randomized intervention arms were pooled after no between-arm trajectory differences in the primary analysis. This coefficient is not an isolated treatment effect.

FFI-RS trajectory difference associated with bilateral versus unilateral pain1 reported outcome
07
Baseline to 12-month trajectory; time × pain laterality interaction

FFI-RS trajectory difference associated with bilateral versus unilateral pain

Foot Function Index Revised Short Form (0–100) FFI-RS points per model time unit

β interaction2.45CI 95% 0.82 to 4.08p <0.01

Difference in modeled time trajectory: bilateral versus unilateral pain

200 participants in this estimate

Linear mixed-effects model

-0.5Equal results 04.6

The interaction indicates a different modeled trajectory for bilateral versus unilateral pain; it is not a randomized treatment effect.

Analysis details and source

Coefficient per model-coded time unit; the time-unit coding is not specified in the table. The authors report that participants with bilateral pain improved in pain at rest and foot function up to 6 months but showed a lack of improvement from 6 to 12 months. The Results text says the final FFI-RS model included "the quadratic time interaction of bilateral pain", but Table 4 prints only a "Time × bilateral pain" row; the paper does not say whether this coefficient is the linear or the quadratic term.

Pain during activity4 reported outcomes
08
Baseline

Pain during activity — cohort mean at baseline

PainA NRS points

Cohort-level descriptive mean 6.31 (SD 1.91); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

09
3 months

Pain during activity — cohort mean at 3 months

PainA NRS points

Cohort-level descriptive mean 4.32 (SD 2.55); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

10
6 months

Pain during activity — cohort mean at 6 months

PainA NRS points

Cohort-level descriptive mean 3.56 (SD 2.63); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

11
12 months

Pain during activity — cohort mean at 12 months

PainA NRS points

Cohort-level descriptive mean 2.81 (SD 2.59); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

Pain at rest4 reported outcomes
12
Baseline

Pain at rest — cohort mean at baseline

PainR NRS points

Cohort-level descriptive mean 3.74 (SD 2.41); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

13
3 months

Pain at rest — cohort mean at 3 months

PainR NRS points

Cohort-level descriptive mean 2.79 (SD 2.38); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

14
6 months

Pain at rest — cohort mean at 6 months

PainR NRS points

Cohort-level descriptive mean 2.30 (SD 2.34); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

15
12 months

Pain at rest — cohort mean at 12 months

PainR NRS points

Cohort-level descriptive mean 1.86 (SD 2.40); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

Foot Function Index Revised Short Form4 reported outcomes
16
Baseline

Foot Function Index Revised Short Form — cohort mean at baseline

FFI-RS FFI-RS points

Cohort-level descriptive mean 45.36 (SD 18.06); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

17
3 months

Foot Function Index Revised Short Form — cohort mean at 3 months

FFI-RS FFI-RS points

Cohort-level descriptive mean 32.38 (SD 22.27); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

18
6 months

Foot Function Index Revised Short Form — cohort mean at 6 months

FFI-RS FFI-RS points

Cohort-level descriptive mean 26.64 (SD 22.31); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

19
12 months

Foot Function Index Revised Short Form — cohort mean at 12 months

FFI-RS FFI-RS points

Cohort-level descriptive mean 21.84 (SD 21.75); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

RAND-12 physical component summary4 reported outcomes
20
Baseline

RAND-12 physical component summary — cohort mean at baseline

PCS12 RAND-12 points

Cohort-level descriptive mean 39.30 (SD 9.45); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

21
3 months

RAND-12 physical component summary — cohort mean at 3 months

PCS12 RAND-12 points

Cohort-level descriptive mean 42.85 (SD 11.00); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

22
6 months

RAND-12 physical component summary — cohort mean at 6 months

PCS12 RAND-12 points

Cohort-level descriptive mean 45.88 (SD 11.27); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

23
12 months

RAND-12 physical component summary — cohort mean at 12 months

PCS12 RAND-12 points

Cohort-level descriptive mean 47.20 (SD 10.88); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

RAND-12 mental component summary4 reported outcomes
24
Baseline

RAND-12 mental component summary — cohort mean at baseline

MCS12 RAND-12 points

Cohort-level descriptive mean 42.29 (SD 10.71); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

25
3 months

RAND-12 mental component summary — cohort mean at 3 months

MCS12 RAND-12 points

Cohort-level descriptive mean 43.89 (SD 12.13); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

26
6 months

RAND-12 mental component summary — cohort mean at 6 months

MCS12 RAND-12 points

Cohort-level descriptive mean 46.12 (SD 12.25); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

27
12 months

RAND-12 mental component summary — cohort mean at 12 months

MCS12 RAND-12 points

Cohort-level descriptive mean 47.09 (SD 12.09); this is not assigned to an intervention arm and is not an ESWT treatment effect.

Analysis details and source

Table 2 observed cohort mean (SD), distinct from the mixed-model coefficient in Tables 3–4. No arm-level estimate or outcome-specific n is reported in this row.

How treatment was delivered
Shared care

Standardized oral and written advice plus customized semi-rigid foot orthosis for all participants.

Randomized add-on groups

Orthosis/advice alone, or with radial ESWT, sham radial ESWT, or heavy-slow exercises. This article refers to the parent protocol for detailed settings and does not report device parameters or session schedule.

HARMS & TOLERABILITY

Adverse events are not reported in this secondary trajectory article.

LIMITS OF THE ANALYSIS

The authors note that participants in an RCT may not represent the broader plantar-fasciopathy population.

Twenty percent did not attend the 3-month visit; under 10% were lost at one year. Model-based missing-data handling may be biased if missingness was not random.

The bilateral-pain trajectory findings require replication.

Treatment arms are combined for this secondary analysis; it does not isolate ESWT efficacy.

Detailed device, dose and session parameters are in the cited parent protocol, which was not part of this article source and was not used to populate this package.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The authors note that participants in an RCT may not represent the broader plantar-fasciopathy population.
  • Twenty percent did not attend the 3-month visit; under 10% were lost at one year. Model-based missing-data handling may be biased if missingness was not random.
  • The bilateral-pain trajectory findings require replication.
  • Treatment arms are combined for this secondary analysis; it does not isolate ESWT efficacy.
  • Detailed device, dose and session parameters are in the cited parent protocol, which was not part of this article source and was not used to populate this package.
Research review

Source-linked critical reading

Secondary trajectory analysis of a randomized trial

Reading depthMaterial consulted
Technical source record

Full text read: all 17 sections, Tables 1–4 and footnotes, Figures 1–3 captions, and disclosure/data statements. Raw XML has four table-wraps, matching parsed tables. Parent-trial protocol is cited but not included in this article source; it was not used to fill device settings or treatment details.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Secondary longitudinal analysis of a sham-controlled, observer-blinded and partly patient-blinded four-arm randomized trial. The parent trial is registered as NCT03472989. This article models recovery across the combined cohort after finding no trajectory differences between intervention arms in the primary analysis.

Participants

200 adults aged 18–70 years were enrolled from a specialized Oslo University Hospital outpatient clinic. Eligibility required heel pain for over three months, localized plantar fascia insertion tenderness and activity pain NRS ≥3. 160–182 participants attended each follow-up (3, 6 and 12 months); 76 (38%) had bilateral pain.

Treatment context

All participants received standardized advice and customized semi-rigid foot orthoses. They were randomized to orthoses/advice alone or with radial ESWT, sham radial ESWT, or heavy-slow exercises. This trajectory paper refers readers to the parent protocol and primary analysis for detailed intervention delivery; device settings and session parameters are not reported here.

Comparators

Four randomized groups are named, but this secondary analysis combines participants because the primary mixed models found no differences among intervention-arm trajectories. The article does not present a new pairwise treatment comparison.

Outcomes

Pain during activity and rest used an 11-point NRS (0–10). Foot function used FFI-RS (0–100; lower is better). Health-related quality of life used RAND-12 physical and mental component scores (0–100; higher is better). Assessments were baseline and 3, 6 and 12 months. Linear mixed models used maximum-likelihood handling of missing values.

Results

Across the cohort, mean activity pain fell from 6.31 (SD 1.91) at baseline to 2.81 (2.59) at 12 months; rest pain 3.74 (2.41) to 1.86 (2.40); FFI-RS 45.36 (18.06) to 21.84 (21.75); PCS12 39.30 (9.45) to 47.20 (10.88); MCS12 42.29 (10.71) to 47.09 (12.09). All changes over time were reported p<0.001. The source reports within-cohort effect sizes of 1.56, 0.78, 1.18, 0.78 and 0.41, respectively; these are not between-group treatment effects. Bilateral pain was associated with a different trajectory in pain at rest and foot function; the bilateral group showed a lack of improvement in these outcomes from 6 to 12 months.

Harms

The article does not report adverse-event outcomes for this secondary trajectory analysis. This is not evidence of no harms in the parent trial.

Limitations

Authors note that a selected RCT sample may not represent usual clinical populations, 20% did not attend the three-month follow-up, follow-up loss at one year was under 10%, and model-based missing-data handling may be biased if missingness was not random. Trajectory findings for bilateral pain require replication. Treatment trajectories were pooled after no differences between parent trial arms were found; this paper is not an ESWT-versus-control efficacy analysis.

Applicability

The results describe recovery in a selected outpatient cohort receiving advice and orthoses, with randomized add-on treatment varying. They do not isolate ESWT effects. Bilateral symptoms were associated with slightly less improvement in rest pain and function and a lack of improvement from 6 to 12 months, which may inform follow-up planning but is not a validated individual prognosis.

Future work

Authors call for replication of bilateral-pain trajectories, investigation of bilateral pain causes and evaluation of treatment strategies for this subgroup.

THE ORIGINAL SOURCE

Read the original article.

One-Year Trajectory of Pain, Function, and Health-Related Quality of Life in Patients With Plantar Fasciopathy.

Røe C, Heide M, Søberg HL, Brunborg C, Hoksrud AF, Myhre K, Brox JI, Mørk M. · Journal of foot and ankle research · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →